Shire PLC Company Profile (NASDAQ:SHPG)

Shire PLC trades on the NASDAQ under the ticker symbol "SHPG."

Shire PLC declared a semiannual dividend on Friday, August 11th. Investors of record on Friday, September 8th will be given a dividend of $0.1527 per share on Friday, October 20th. This represents a dividend yield of 0.21%. The ex-dividend date is Thursday, September 7th. View Shire PLC's Dividend History.

Shire PLC (NASDAQ:SHPG) released its quarterly earnings results on Friday, October, 27th. The company reported $3.37 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $3.66 by $0.29. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. View Shire PLC's Earnings History.

Shire PLC is scheduled to release their next quarterly earnings announcement on Friday, October, 27th 2017. View Earnings Estimates for Shire PLC.

Shire PLC updated its FY17 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of $14.80-15.20 for the period, compared to the Thomson Reuters consensus estimate of $14.85. The company issued revenue guidance of $14.9-15.3 billion, compared to the consensus revenue estimate of $15.04 billion.

21 brokers have issued 1-year price targets for Shire PLC's shares. Their forecasts range from $159.00 to $325.00. On average, they expect Shire PLC's share price to reach $220.91 in the next year. View Analyst Ratings for Shire PLC.

Here are some recent quotes from research analysts about Shire PLC stock:

• 1. Cantor Fitzgerald analysts commented, "This morning, SHPG announced that the Marketing Authorization Application (MAA) for Lifitegrast has been validated by the UK as the Reference Member State involved in the Decentralized Procedure (DCP)." (8/15/2017)
• 2. According to Zacks Investment Research, "Shire reported encouraging Q2 results, beating estimates for both sales and earnings.The approval of Mydayis is likely to boost Shire’s ADHD segment dominance while strong performance of Vyvanse, Cinryze and Elaprase will continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology space, acquiring roughly 23% of the total market by the end of Jun 2017. The Dyax acquisition has integrated well and Shire announced positive results from the phase III trial on lanadelumab in May 2017. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Moreover, shares have underperformed the industry." (8/8/2017)
• 3. Jefferies Group LLC analysts commented, "SHPG posted strong 4Q16 revs ($3.8B vs $3.7B JEF) and EPS ($3.37 vs $3.26 JEF) as nearly all core franchises performed well. In particular, GI and Orphan Diseases showed strength. As for legacy BXLT, Immunoglobulins and Hemophilia performed well while Inhibitors lagged. We like the setup for 2017. If mgt executes on core brands, the Xiidra launch, and the BXLT integration, we could envision share price outperformance, augmented by significant deleveraging." (2/17/2017)

Shire PLC saw a increase in short interest during the month of August. As of August 31st, there was short interest totalling 1,535,236 shares, an increase of 32.5% from the August 15th total of 1,158,579 shares. Based on an average trading volume of 1,336,807 shares, the days-to-cover ratio is presently 1.1 days.

Some companies that are related to Shire PLC include Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Dr. Reddy's Laboratories Ltd (RDY), Patheon NV (PTHN), Catalent (CTLT), Valeant Pharmaceuticals International (VRX), Taro Pharmaceutical Industries (TARO), Akorn (AKRX), Opko Health (OPK), Hikma Pharmaceuticals Plc (HIK), BTG plc (BTG), Amicus Therapeutics (FOLD) and Corcept Therapeutics Incorporated (CORT).

Shire PLC's management team includes the folowing people:

• Flemming Ornskov M.D., Chief Executive Officer, Executive Director
• Jeffrey Poulton, Chief Financial Officer, Executive Director
• Joanne Cordeiro, Chief Human Resource Officer
• William Mordan, General Counsel, Company Secretary
• Perry Sternberg, Head - U.S. Commercial
• Kim Stratton, Head - International Commercial
• Philip J. Vickers, Head - Research and Development
• Matthew Walker, Head - Technical Operations
• Susan Saltzbart Kilsby, Independent Non-Executive Chairman of the Board
• Olivier Bohuon, Non-Executive Director

Shire PLC's stock is owned by a number of of institutional and retail investors. Top institutional investors include Jennison Associates LLC (0.00%), Maverick Capital Ltd. (0.00%), Glenview Capital Management LLC (0.00%), FMR LLC (0.53%), Ameriprise Financial Inc. (0.51%) and Vanguard Group Inc. (0.49%). View Institutional Ownership Trends for Shire PLC.

Shire PLC's stock was sold by a variety of institutional investors in the last quarter, including Jennison Associates LLC, FMR LLC, Voya Investment Management LLC, Arrowstreet Capital Limited Partnership, BlackRock Inc., Sphera Funds Management LTD., Sei Investments Co. and Capital Fund Management S.A.. View Insider Buying and Selling for Shire PLC.

Shire PLC's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Glenview Capital Management LLC, Northern Trust Corp, OZ Management LP, Maverick Capital Ltd., Harding Loevner LP, Ameriprise Financial Inc. and Farallon Capital Management LLC. View Insider Buying and Selling for Shire PLC.

Shares of Shire PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Shire PLC stock can currently be purchased for approximately $155.51.